Urologic Oncology: Seminars and Original Investigations This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Table of Contents
(Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - August 1, 2018 Category: Urology & Nephrology Source Type: research

Mechanisms and funding opportunities in genitourinary cancer clinical research
Progress in the prevention, diagnosis, and treatment of genitourinary cancers is dependent on well-conducted clinical trials. The complexity and cost of clinical research continues to escalate, and success is dependent on adequate funding. Opportunities to fund such research include federal, industry, and private sources. The mechanisms whereby larger trials are conducted include contract research organizations, publically- and privately funded consortia, and the National Clinical Trials Network of the National Cancer Institute. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - August 1, 2018 Category: Urology & Nephrology Authors: Christopher W. Ryan Tags: Seminars article Source Type: research

Robust method for isolation of tumor infiltrating lymphocytes with a high vital cell yield from small samples of renal cell carcinomas by a new collagenase-free mechanical procedure
Since the last decade, therapeutic options for the treatment of advanced renal cell carcinoma (RCC) increased considerably. The checkpoint-inhibitor therapy has emerged as a new treatment regimen with promising outcome [1 –3]. This is exemplified by inhibitors targeting the programmed death-1/programmed death-ligand-1 (PD-1/PD-L1) molecules [4] which have shown impressive improvements in treatment responses and patient survival [5,6]. Despite this success, response rates still remain only in the range of 20% [7], w hich emphasizes the need for increased knowledge on immunopathogenesis of RCC and on the role and phenotypi...
Source: Urologic Oncology: Seminars and Original Investigations - July 30, 2018 Category: Urology & Nephrology Authors: Fiona Crossey, Stefanie Marx, Sebastian H ölters, Kai Schmitt, Rainer M. Bohle, Tina Schmidt, Michael Stöckle, Urban Sester, Martina Sester, Martin W.W. Janssen Source Type: research

An immediate, single intravesical instillation of mitomycin C is of benefit in patients with non –muscle-invasive bladder cancer irrespective of prognostic risk groups
The treatment of non –muscle-invasive bladder cancer (NMIBC) remains a challenge because of its tendency to recur and progress [1,2]. To decrease the risk of recurrence, an immediate instillation of chemotherapy after transurethral resection (TURBT) is administered. The instillation prevents recurrence through eradica tion of floating tumor cells and residual tumor at the tumor site and by eradication of small overlooked synchronous tumors [3,4]. A recent systematic review and individual patient data meta-analysis by Sylvester et al. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - July 29, 2018 Category: Urology & Nephrology Authors: Judith Bosschieter, Jakko A. Nieuwenhuijzen, Andr é N. Vis, Tessa van Ginkel, Birgit I. Lissenberg-Witte, Goedele M.A. Beckers, R. Jeroen A. van Moorselaar Tags: Original article Source Type: research

Female radical cystectomy patients have a higher risk of surgical site infections
Radical cystectomy is associated with frequent and often severe adverse events. As systems for recording patient outcomes have become more sensitive and comprehensive over time, the reported risk of adverse events has increased from 20% to 30% in early 1980s to upward of 80% in recent publications [1 –8]. Higher quality data pertaining to adverse events have allowed for more accurate patient counseling and have identified specific complications that may be targeted for improvement with interventions. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - July 28, 2018 Category: Urology & Nephrology Authors: Hamidreza Abdi, Ehab Elzayat, Ilias Cagiannos, Luke T. Lavall ée, Sonya Cnossen, Anathea S. Flaman, Ranjeeta Mallick, Chris Morash, Rodney H. Breau Tags: Original article Source Type: research

Introduction to “Molecular drivers of prostate cancer development, progression, and resistance to therapy”
This seminar focuses on the molecular features of prostate cancer, the impact of specific alterations on the biology, and clinical features of the disease, and how we will leverage this information in the future for patient benefit. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - July 28, 2018 Category: Urology & Nephrology Authors: Christopher E. Barbieri Tags: Seminars article Source Type: research

Radical prostatectomy then and now: Surgical overtreatment of prostate cancer is declining from 2009 to 2016 at a tertiary referral center
Overtreatment of prostate cancer (CaP) remains an obstacle in delivering high quality care to these patients. Radical prostatectomy (RP) for nonlethal cancers has been reported in as many as 40% of cases in some series [1 –5]. The possibility for undesirable sequelae of RP is well-known [6,7], reinforcing the consensus that the operation be restricted to cancers of serious potential [8]. An appreciation of the overtreatment issue has resulted in increased use of active surveillance for low-risk lesions [8]. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - July 28, 2018 Category: Urology & Nephrology Authors: Amirali Salmasi, Izak Faiena, Jason Wu, Anthony E. Sisk, Ankush Sachveda, Jacob J. Vandel, Karim Chamie, Leonard S. Marks, Robert E. Reiter Tags: Original Article Source Type: research

Cover 2 -- Masthead
(Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - June 16, 2018 Category: Urology & Nephrology Source Type: research

Editorial Board
(Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - June 16, 2018 Category: Urology & Nephrology Source Type: research

Table of Contents
(Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - June 16, 2018 Category: Urology & Nephrology Source Type: research

Survey Section Editorial Board
(Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - June 16, 2018 Category: Urology & Nephrology Source Type: research

Current controversies on the role of lymphadenectomy for bladder cancer
Significant evidence exists regarding the diagnostic and therapeutic roles of pelvic lymph node dissection at the time of radical cystectomy for patients with bladder cancer. Despite this, lymphadenectomy for bladder cancer is still underutilized and even where performed, controversies exist in regard to what defines an adequate dissection and whether or not the indications for lymphadenectomy have changed now that we are firmly entrenched in the neoadjuvant chemotherapy era. A comprehensive literature review was performed to touch on these important issues and highlight future directions and current trials that will soon ...
Source: Urologic Oncology: Seminars and Original Investigations - June 14, 2018 Category: Urology & Nephrology Authors: Saum Ghodoussipour, Siamak Daneshmand Tags: Seminars article Source Type: research

Decreased expression of serine protease inhibitor family G1 (SERPING1) in prostate cancer can help distinguish high-risk prostate cancer and predicts malignant progression
The aim of this study was to investigate the associations of serine proteinase inhibitor family G1 (SERPING1) down-regulation with poor prognosis in patients with prostate cancer (PCa). Furthermore, we aim to find more novel and effective PCa molecular markers to provide an early screening of PCa, distinguish patients with aggressive PCa, predict the prognosis, or reduce the economic burden of PCa. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - June 11, 2018 Category: Urology & Nephrology Authors: Shengmeng Peng, Tao Du, Wanhua Wu, Xianju Chen, Yiming Lai, Dingjun Zhu, Qiong Wang, Xiaoming Ma, Chunhao Lin, Zean Li, Zhenghui Guo, Hai Huang Tags: Original article Source Type: research

Detailed analysis of patient-reported lower urinary tract symptoms and effect on quality of life after robotic radical prostatectomy
To prospectively evaluate short- to medium-term patient-reported lower urinary tract symptoms (LUTS) and their effect on health-related quality of life (HRQoL) using validated questionnaires in a large cohort of patients following robotic-assisted radical prostatectomy (RARP) for prostate cancer. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - June 9, 2018 Category: Urology & Nephrology Authors: Jonathan J. Aning, Kenneth R. MacKenzie, Michael Fabricius, Elaine McColl, Mark I. Johnson, Zafer Tandogdu, Naeem A Soomro, Christopher Harding Tags: Original article Source Type: research

Re: “Current surgical standards of care in Wilms tumor”
The authors have published a valuable article that outlines the current status of surgical care in Wilms tumor, highlighting key technical points as well as addressing areas of controversy and future research directions. One point to clarify for the readership [1]: (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - June 8, 2018 Category: Urology & Nephrology Authors: Kiarash Taghavi Tags: Letter to the Editor Source Type: research